Skip to content

Mazdutide vs Tirzepatide

Updated 5 sources

Key differences

  1. 1Tirzepatide pairs GLP-1 with GIP. Mazdutide pairs GLP-1 with glucagon.
  2. 2Tirzepatide is FDA approved. Mazdutide is approved only in China.
  3. 3No head-to-head trial exists.

Side by side

Facts from each record, in the same words as their own pages.
Mazdutide and Tirzepatide side by side
MazdutideTirzepatide
Category
  • GLP-1, Weight loss
  • GLP-1, Weight loss
Evidence
  • Strong human trials
  • Strong human trials
FDA status
  • In clinical trialsRegulatory
  • FDA approved as Mounjaro +1Regulatory
WADA
  • Not prohibited
  • Not prohibited
Half-life
  • 6.3 to 16.8 days after the first dose in a phase 1b trial in Chinese adults; peak levels at a median of 72 hours.Clinical study
  • About 5 days (Mounjaro label); 5 to 6 days in people with obesity or sleep apnea (Zepbound label). That is why it is dosed once a week.Regulatory
Routes
  • Subcutaneous injection
  • Subcutaneous injection
Forms
  • Prefilled pen, Vial (powder)
Not reported
Reported doses
  • 1 to 16 mg (subcutaneous injection)
  • 0.25 to 15 mg (subcutaneous injection)
Most cited frequency
  • Once weekly: 2 mg for 4 weeks, 4 mg for 4 weeks, then 4 or 6 mg to maintain
  • Once weekly. Step up 2.5 mg after at least 4 weeks only if needed, then hold the maintenance dose.
Vial sizes
  • 5 mg, 10 mg, 15 mg, 20 mgCompetitor guide
  • 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mgCompetitor guide
Mixed vial keeps
  • Keep the mixed vial in the fridge at 2 to 8 C and never freeze it.Competitor guide
  • Keep the mixed vial in the fridge and use it within about 28 days.Competitor guide
Protocols on file
  • 13
  • 12

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

5 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Regulatory4

  1. Mounjaro and Mounjaro KwikPen label, rev. 8/2026DailyMed · checked Oct 24, 2026
  2. Zepbound Prescribing Information, rev. 04/2026FDA · checked Oct 24, 2026
  3. Mazdutide: First ApprovalDrugs (PubMed record), via a reference work · checked Oct 24, 2026
  4. Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 DiabetesInnovent Biologics (via BioSpace), via a news report · checked Oct 24, 2026